Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Adicet Bio Inc (ACET)
Adicet Bio Inc (ACET)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 256,871
  • Shares Outstanding, K 42,955
  • Annual Sales, $ 24,990 K
  • Annual Income, $ -69,790 K
  • 60-Month Beta 2.35
  • Price/Sales 11.29
  • Price/Cash Flow N/A
  • Price/Book 0.96
Trade ACET with:

Options Overview Details

View History
  • Implied Volatility 115.97% ( -27.32%)
  • Historical Volatility 76.87%
  • IV Percentile 65%
  • IV Rank 27.39%
  • IV High 241.77% on 05/26/22
  • IV Low 68.53% on 06/17/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 55
  • Volume Avg (30-Day) 114
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 2,370
  • Open Int (30-Day) 1,959

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.74
  • Number of Estimates 2
  • High Estimate -0.70
  • Low Estimate -0.78
  • Prior Year 0.10
  • Growth Rate Est. (year over year) -840.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.64 +2.66%
on 03/23/23
8.15 -29.00%
on 03/14/23
-2.29 (-28.34%)
since 02/23/23
3-Month
5.64 +2.66%
on 03/23/23
9.52 -39.21%
on 02/02/23
-2.14 (-26.99%)
since 12/23/22
52-Week
5.64 +2.66%
on 03/23/23
21.87 -73.53%
on 11/11/22
-10.77 (-65.04%)
since 03/23/22

Most Recent Stories

More News
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights...

ACET : 5.79 (-3.18%)
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 5.79 (-3.18%)
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -21.95% and 1.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AKYA : 7.69 (-3.03%)
ACET : 5.79 (-3.18%)
Myriad Genetics (MYGN) Reports Q4 Loss, Tops Revenue Estimates

Myriad (MYGN) delivered earnings and revenue surprises of 25% and 5.11%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

MYGN : 23.63 (+3.14%)
ACET : 5.79 (-3.18%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on February...

ACET : 5.79 (-3.18%)
Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod

Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients....

GILD : 78.76 (+1.22%)
ACET : 5.79 (-3.18%)
ADMA : 3.11 (+3.32%)
ETNB : 16.94 (+23.83%)
Karuna (KRTX) to Obtain Global Rights to Goldfinch's Candidates

Karuna Therapeutics (KRTX) announces a definitive agreement with Goldfinch Bio to acquire global rights to the latter's lead clinical-stage candidate, GFB-887 and TRPC4/5 channel candidates.

ACET : 5.79 (-3.18%)
ADMA : 3.11 (+3.32%)
KRTX : 176.22 (+3.98%)
ETNB : 16.94 (+23.83%)
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 5.79 (-3.18%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on January...

ACET : 5.79 (-3.18%)
Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

BIIB : 265.17 (+1.51%)
LLY : 332.64 (+0.50%)
ACET : 5.79 (-3.18%)
ACIU : 2.19 (+2.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.

See More

Key Turning Points

3rd Resistance Point 7.39
2nd Resistance Point 7.08
1st Resistance Point 6.53
Last Price 5.79
1st Support Level 5.67
2nd Support Level 5.36
3rd Support Level 4.81

See More

52-Week High 21.87
Fibonacci 61.8% 15.67
Fibonacci 50% 13.76
Fibonacci 38.2% 11.84
Last Price 5.79
52-Week Low 5.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar